Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

VolitionRx Limited raises around US$12.8mln from share offer

Cancer diagnostics group VolitionRx Limited has raised around US$12.8mln from its share placing, which will be used to further the business, including for clinical studies and product commercialisation.
VolitionRx Limited raises around US$12.8mln from share offer
Last week the group priced its US$12.25mln placing at US$3.25 per share, around a 10% discount to the market price at the time...

Cancer diagnostics group VolitionRx Limited (NYSE:VNRX) has raised around US$12.8mln from its share placing, which will be used to advance the business, including for clinical studies and product commercialisation.

Last week the group priced its US$12.25mln placing at US$3.25 per share, around a 10% discount to the market price at the time.

The firm issued around 3.7mln shares and a further 565,384 additional stock as the over-allotment option was taken in full.

"VolitionRx intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes," it said.

The company has developed the NuQ diagnostic test that measures nucleosomes in the bloodstream – an indication that cancer is present.

Results have been encouraging in trials so far for colorectal, lung and prostate cancer with detection rates of over 90%.

The company is currently going through the approval process for a European CE mark and expects a commercial launch of the test this year for clinical use in Europe, with meaningful sales expected to begin in 2017.

Giles_55af4ddca6481.jpg


Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

Related Articles

Microscope
March 24 2016
Shares were placed at 35p each, a discount of around 4.3% to Tuesday night's close.
rsz_shutterstock_118277080.jpg
August 02 2016
Horizon Discovery is a machine, which keeps motoring, underlined by the life sciences group's positive update on 2015 trading.
Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.